Orphazyme buyer intends to resubmit failed drug candidate for FDA approval
US-based Kempharm, which has taken over all assets and business activities from Orphazyme, is planning to succeed where the Danish biotech company failed by resubmitting arimoclomol next year.
by christopher due karlsson, translated by daniel pedersen
Kempharm, the new US-based owner of all assets of embattled biotech company Orphazyme, is expecting to have a resubmission of a market authorization application for arimoclomol ready next year, according to the company’s second-quarter report released earlier this month.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme co-founder becomes board chair at biotech startup
For subscribers
Orphazyme reports USD 90m deficit for 2021
For subscribers
